Beacon Biosignals, a Boston, MA-based computational neurodiagnostics and electroencephalogram (EEG) analytics company, acquired Dreem, a Paris, France-based company which specializes in at-home sleep monitoring.
The amount of the deals as not disclosed.
This strategic acquisition signifies a remarkable milestone, setting the stage for clinical trial assessments at scale via the integration of Dreem’s clinically-validated hardware with Beacon’s EEG analytics platform.
Founded in 2014, Dreem is a a market leader in developing clinically-validated sleep monitoring devices. Its advanced headset, Dreem 3, is a patient-centric sleep headband that has been deployed in numerous biopharma-sponsored clinical studies and has been clinically validated against standard polysomnography (Arnal et al., Sleep 2020). The lightweight, low-profile Dreem 3 device is engineered to optimize EEG signal quality, patient comfort and operational efficiency. Backed by over $57M in funding, Dreem built an intellectual property portfolio and a regulatory strategy around its innovative sleep monitoring technologies that have been used to record over two million nights of sleep.
Led by Jacob Donoghue MD PhD, CEO, Beacon provides a machine learning platform for EEG that enables and accelerates new treatments for patients with neurological, psychiatric or sleep disorders through machine learning algorithms, clinically-validated EEG wearables, large Clinico-EEG RWE datasets, and advances in cloud-based scientific computing.
As part of this acquisition, Beacon Biosignals secured an undisclosed financing round with participation from its syndicate of Series A investors, led by General Catalyst.
FinSMEs
13/07/2023